Skip to content
    Real-World Studies

    En bloc resection of bladder tumor shows favorable safety in multicenter cohort

    Yanagisawa et alInternational Journal of Urology

    In a multicenter real-world study evaluating 668 patients across five institutions, en bloc resection of bladder tumor (ERBT) demonstrated favorable perioperative safety, reliable detrusor muscle retrieval, and acceptable long-term oncological outcomes. The cohort had a median age of 73 years and a median maximum tumor diameter of 15 mm. The median operative time was 48 minutes, and the median postoperative catheterization duration was 3 days.
    Perioperative complications were documented in 9.0% of patients (n = 60), with high-grade complications (Clavien-Dindo Grade III or higher) limited to 1.2% (n = 8). Pathologically, detrusor muscle was identified in 77.2% of evaluable specimens, confirming high-quality muscularis propria sampling. Final histopathological staging identified pTa disease in 56.4% (n = 377), pT1 in 35.8% (n = 239), pTis in 2.4% (n = 16), and muscle-invasive pT2 disease in 3.7% (n = 25).
    Long-term oncological outcomes were analyzed in 551 patients with pathologically confirmed non-muscle-invasive bladder cancer (NMIBC) and no prior history of upper tract urothelial carcinoma over a median follow-up of 42 months. The estimated recurrence-free survival (RFS) rates were 80.9% at 1 year, 73.2% at 2 years, and 57.1% at 5 years. RFS did not differ significantly between patients with pTa and pT1 disease (log-rank p = 0.39). However, Cox proportional hazards regression identified prior recurrence status as a critical prognosticator: patients presenting with recurrent disease exhibited a more than two-fold higher risk of subsequent intravesical recurrence compared with those presenting with primary lesions (HR 2.06, 95% CI 1.38–3.07; p < 0.001), underscoring the necessity of risk-stratified postoperative surveillance.

    Key Takeaways

    • En bloc resection of bladder tumor (ERBT) demonstrated a 9.0% overall perioperative complication rate, with severe adverse events (Clavien-Dindo Grade ≥III) occurring in only 1.2% of patients, and achieved detrusor muscle capture in 77.2% of evaluable specimens.
    • In non-muscle-invasive bladder cancer, estimated recurrence-free survival after ERBT was 80.9% at 1 year, 73.2% at 2 years, and 57.1% at 5 years, with no statistically significant difference between pTa and pT1 stages (log-rank p = 0.39).
    • Patients presenting with recurrent tumors experienced a significantly higher risk of subsequent intravesical recurrence compared with those presenting with primary tumors (HR 2.06, 95% CI 1.38–3.07; p < 0.001).
    Read the original sourceInternational Journal of Urology